Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Lymphoma, Extranodal NK-T-Cell 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Down Syndrome 3Lymphoma 2Leukemia, Myeloid, Acute 2Lymphohistiocytosis, Hemophagocytic 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

zanubrutinib 1pegaspargase 1Rituximab 1Methylprednisolone 1Etoposide 1Asparaginase 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphohistiocytosis, Hemophagocytic × pegaspargase × 1 year × Clear all
NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Beijing Tongren Hospital

Phase 1/2 Recruiting
25 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡